Is Albemarle Stock Outperforming the S&P 500?
Albemarle reported a 155% year-over-year increase in adjusted EBITDA to $858.1M, with margins expanding to 49%. Shares rose 5.5% post-results. Rival Linde (LIN) gained 7.3% year-to-date but trailed ALB over 52 weeks. Analysts rate ALB 'Moderate Buy' with a $176.77 mean target, implying 56.5% upside.






